Outcome of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Genetic Features

Benzer Materyaller

• Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach
  Yazar:: Stephens, Deborah M., ve diğerleri
  Baskı/Yayın Bilgisi: (2012)
• Reduced Occurrence of Tumor Flare with Flavopiridol Followed by Combined Flavopiridol and Lenalidomidein Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Yazar:: Maddocks, Kami, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
  Yazar:: Rogers, Kerry A., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
  Yazar:: Lin, Thomas S., ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center
  Yazar:: Stephens, Deborah M., ve diğerleri
  Baskı/Yayın Bilgisi: (2014)